SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN)
BTRN 35.28+0.5%Nov 5 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (1256)2/25/2002 4:02:36 PM
From: aknahow  Read Replies (1) of 1475
 
OTHER PSORIASIS DRUGS At AAD: MEDI-507, ABX-IL8, And ISIS 2302

MedImmune's (MEDI - #) MEDI-507 (humanized anti-CD2 antibody) is
subject of a
poster (P23) providing additional analysis from previously described
Phase I/II
studies in which MEDI-507 demonstrates efficacy at T-cell depleting
doses that
is in the range generally seen with competing biologics. In our
view, MEDI-507
could see approval in 2004 and has peak sales potential of $300
million.
MEDI-507 could be differentiated from other anti-CD2 strategies by
its side
effect profile and by virtue of its subcutaneous dosing, which may
allow dosing
frequency or once/week or less often. Anecdotes from clinical
investigators
suggest that in small studies, MEDI-507 provides disease remissions
that appear
comparable to those seen with Amevive. Abgenix's ABX-IL-8 (fully
human anti-IL-8
antibody) is the subject of a poster presentation at AAD. In our
view, the
results show only modest activity against severe psoriasis, and IL-8
may not be
an ideal molecular target in psoriasis, potentially acting too far
downstream in
the pathogenesis of disease. ISIS's ISIS-2302 (antisense ICAM-1
inhibitor) is
the subject of a poster describing results in psoriasis with a
topical
formulation in which there was a trend toward efficacy in a small
clinical
study.

From U.S. Bancorp Piper Jaffray

Interested in BTRN currently no position.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News